The INTerpath-001 trial is evaluating Moderna/Merck’s mRNA-4157 in combination with Merck’s Keytruda
Category: melanoma
The phase 1/2 Mobilize trial is evaluating the safety and efficacy of mRNA-4359
Vd1-gd T cells were effective in predicting positive responses to ICI therapy